– USA, MA – Intrinsic Therapeutics, Inc., the developer of the Barricaid, an FDA-approved medical device proven to significantly reduce herniations and reoperations following lumbar discectomy surgery, today announced the appointment of Dave Amerson and Tyler Binney to its Board of Directors.
“I am thrilled to welcome Dave and Tyler to the Intrinsic board and I am confident they will help drive rapid growth and add huge value to the company. I worked closely with both Dave and Tyler during my time as a board member at NeoTract so I have firsthand knowledge of their amazing talent for driving commercial growth.” said Board Chairman, Ryan Drant.
About Dave Amerson
Dave Amerson served as President and CEO of NeoTract, Inc. until its acquisition by Teleflex in 2017 for $1.1 billion. Dave previously served as Chairman of the Board at Palette Life Sciences until its acquisition by Teleflex for $600 million in 2023 and was a Board Member of Relievant Medsystems, Inc. until its acquisition by Boston Scientific in 2023. He currently serves on the board of directors of Calyxo, Moximed, Revelle, and the Urology Care Foundation.
Dave Amerson holds an M.B.A. from Argosy University and a B.A. in Political Science from the University of West Georgia.
About Tyler Binney
Tyler Binney is currently President and CEO of Relievant Medsystems, which was recently acquired by Boston Scientific for $850 million plus a performance-based earnout. Before joining Relievant, Tyler served as President and General Manager of Interventional Urology at Teleflex, and as Vice President of Sales for NeoTract. Before NeoTract, Tyler served in multiple leadership roles in sales and marketing at Johnson & Johnson.
Tyler Binney holds a Bachelor of Science in Biology from Presbyterian College.
About Barricaid
Barricaid is a proprietary technology designed to prevent herniation and reoperation in patients with large annular defects following lumbar discectomy surgery. Barricaid has been implanted in more than eleven thousand patients and is supported by clinical studies in eight distinct patient populations, including two randomized controlled trials and six single-armed trials. A multicenter level I RCT demonstrating superior outcomes to discectomy alone with 5-year results was published in JAMA. Recently, the Centers for Disease Control issued ICD-10 codes to track and monitor defect size in discectomy patients, confirming the medical necessity for Barricaid.
For more information: https://barricaid.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
